ArticlePediatric blood & cancer2014
Neonatal medical exposures and characteristics of low birth weight hepatoblastoma cases: a report from the Children's Oncology Group.
Article in Pediatric blood & cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 49 citations in OpenAlex.
- Tumor Topography Remodels TME Signalling via Compartment-Specific Host-Microbiome-Tumor Crosstalk in Hepatoblastoma.Cancers · 2026Article
- Relationship Between Total Parenteral Nutrition, Ventilation, and Hepatoblastoma: A Study of 258,929 Neonatal Intensive Care Unit Admissions.Pediatric blood & cancer · 2025Article
- Hepatoblastoma.Nature reviews. Disease primers · 2025Review
- "Update on pediatric primary liver tumors".Virchows Archiv : an international journal of pathology · 2025Review
- Clinical comparison of radiofrequency ablation and surgical resection in treating pulmonar metastasis of hepatoblastoma.Frontiers in oncology · 2025Article
- An indocyanine green-based liquid biopsy test for circulating tumor cells for pediatric liver cancer.Hepatology communications · 2024Article
- Update on the Pathology of Pediatric Liver Tumors: A Pictorial Review.Diagnostics (Basel, Switzerland) · 2023Review
- Children's Oncology Group's 2023 blueprint for research: Liver tumors.Pediatric blood & cancer · 2023Article
- Anabolic-androgenic anabolic steroids as a probable risk factor for hepatoblastoma in infants.Clinical case reports · 2023Article
- Cisplatin in Liver Cancer Therapy.International journal of molecular sciences · 2023Review
- Primary Liver Cancers: Connecting the Dots of Cellular Studies and Epidemiology with Metabolomics.International journal of molecular sciences · 2023Review
- Upregulation of SERPINE2 Results in Poor Prognosis of Hepatoblastoma via Promoting Invasion Abilities.Disease markers · 2022Article
- Unraveling the Genetic Architecture of Hepatoblastoma Risk: Birth Defects and Increased Burden of Germline Damaging Variants in Gastrointestinal/Renal Cancer Predisposition and DNA Repair Genes.Frontiers in genetics · 2022Article
- Pediatric Primary Hepatic Tumors: Diagnostic Considerations.Diagnostics (Basel, Switzerland) · 2021Review
- Insights Into the Somatic Mutation Burden of Hepatoblastomas From Brazilian Patients.Frontiers in oncology · 2020Article
- Analysis of factors related to recurrence of paediatric hepatoblastoma - a single Centre retrospective study.BMC pediatrics · 2019Article
- Hepatoblastoma-The Evolution of Biology, Surgery, and Transplantation.Children (Basel, Switzerland) · 2018Review
- Maternal and paternal occupational exposures and hepatoblastoma: results from the HOPE study through the Children's Oncology Group.Journal of exposure science & environmental epidemiology · 2017Article
- Maternal Preeclampsia and Odds of Childhood Cancers in Offspring: A California Statewide Case-Control Study.Paediatric and perinatal epidemiology · 2017Article
- Hepatoblastoma modeling in mice places Nrf2 within a cancer field established by mutantJCI insight · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundHepatoblastoma is a malignancy of young children. Low birth weight is associated with significantly increased risk of hepatoblastoma and neonatal medical exposures are hypothesized as contributors. This study represents the largest case-control study of hepatoblastoma to date and aimed to define the role of neonatal exposures in hepatoblastoma risk among low birth weight children. PROCEDURE: Incident hepatoblastoma cases who were born <2,500 g (N = 60), diagnosed between 2000 and 2008, were identified through the Children's Oncology Group. Controls were recruited through state birth registries (N = 51). Neonatal medical exposures were abstracted from medical records. Subjects from the Vermont Oxford Network were used for further comparisons, as were existing reports on neonatal medical exposures.
resultsCase-control comparisons were hindered by poor matching within birth weight strata. Cases were smaller and received more aggressive neonatal treatment compared to controls, and reflected high correlation levels between birth weight and treatments. Similar difficulty was encountered when comparing cases to Vermont Oxford Network subjects; cases were smaller and required more aggressive neonatal therapy. Furthermore, it appears hepatoblastoma cases were exposed to a greater number of diagnostic X-rays than in case series previously reported in the neonatal literature.
conclusionsThis study presents the largest case series of hepatoblastoma in <2,500 g birth weight infants with accompanying neonatal medical exposure data. Findings confirm that birth weight is highly correlated with exposure intensity, and neonatal exposures are themselves highly correlated, which hampers the identification of a causal exposure among hepatoblastoma cases. Experimental models or genetic susceptibility testing may be more revealing of etiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.